Company attributes
Other attributes
Perception Neuroscience, an ATAI Life Sciences company, is a biopharmaceutical company developing arketamine therapy for neuropsychiatric diseases. The company says that its mission is to provide substantially more effective treatment solutions to serious psychiatric disorders.
Perception Neuroscience's products are based on research work by professor Kenji Hashimoto of Chiba University. The company licensed patents based on his work.
A lead product of Perception Neuroscience is the NMDA antagonist arketamine (PCN 101), a single ketamine isomer. Arketamine is part of a new generation of glutamate receptor modulators with the potential for RAAD activity and anti-suicidal effects. These new RAAD medications are anticipated to be more successful than existing FDA-approved antidepressant therapies, which sometimes take weeks to reach full efficacy, if they achieve any efficacy at all.
